🇺🇸 SECKAZIA THERAPEUTICS LTDQwen · 实盘不做把握 4/10不做原因:其他
北京时间·🕒 发布 18:10:16·⟳ 抓取 18:10:55 +39s·⚡ 决策 08-28 18:30:51 +19m56s·60.1 天前
Kazia Therapeutics提交6-K：将ATM增发额度从1亿美元下调至8000万美元
事件方向不明确且重大性存疑：ATM额度下调既可能意味着公司已大量使用增发额度（稀释进行中），也可能是主动缩减发行规模（减轻稀释预期），两种解读方向相反；同时Kazia为微型生物科技股，该行政性备案相对其市值的增量影响难以量化，无法形成明确的正期望交易。
📄 原文KAZIA THERAPEUTICS LTD↗ 原文
----- ea0303789-6k_kazia.htm ----- 6-K 1 ea0303789-6k_kazia.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITI…
不做 Kazia Therapeutics Limited（KZIA.US）
ATM额度下调为行政性备案调整，方向不明确（可能是已用额度的反映，也可能是主动缩减稀释），且Kazia为微型生物科技股，该事件相对其市值的增量影响极小，无法形成明确正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Kazia Therapeutics于2026年8月28日向SEC提交6-K，将2026年3月设立的1亿美元ATM增发额度下调至8000万美元。该事件本质是对已有ATM安排的行政性调整：若公司已使用约2000万美元额度，则下调只是反映剩余额度；若为主动缩减，则可能减轻未来稀释压力。两种解读方向相反，且Kazia为微型生物科技公司，该备案本身不构成独立的重大催化，无法形成明确方向性交易。
🔎 新鲜度:最早出现 2026-08-28 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例可供校准
方向:无足够先例
涨幅量级:无
形态:无
原文全文
展开原文 · 1,862 字
----- ea0303789-6k_kazia.htm -----
6-K
1
ea0303789-6k_kazia.htm
REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2026
Commission File Number: 000-29962
Kazia Therapeutics Limited
(Exact Name of Registrant as Specified in Its Charter)
Three International Towers Level 24, 300 Barangaroo
Avenue, Sydney NSW 2000
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Filing of Prospectus Supplement
On August 28, 2026, Kazia Therapeutics Limited (the “Company”)
filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b)(5) under the Securities Act of 1933, as
amended, with the U.S. Securities and Exchange Commission. The Prospectus Supplement reduces the maximum aggregate offering price of American
Depositary Shares (“ADSs”) that may be offered, issued and sold under the Sales Agreement, dated March 17, 2026 (the “Sales
Agreement”), by and between the Company and Leerink Partners LLC (“Leerink Partners”), from $100,000,000 to $80,000,000.
The
Prospectus Supplement supplements the Company’s registration statement on Form F-3 (File No.
333-294392
), which was initially filed
with the Securities and Exchange Commission on March 18, 2026.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited
By:
/s/ John Friend
Name:
John Friend
Title:
Chief Executive Officer
Date:
August 28, 2026
2
6-K
1
ea0303789-6k_kazia.htm
REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2026
Commission File Number: 000-29962
Kazia Therapeutics Limited
(Exact Name of Registrant as Specified in Its Charter)
Three International Towers Level 24, 300 Barangaroo
Avenue, Sydney NSW 2000
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Filing of Prospectus Supplement
On August 28, 2026, Kazia Therapeutics Limited (the “Company”)
filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b)(5) under the Securities Act of 1933, as
amended, with the U.S. Securities and Exchange Commission. The Prospectus Supplement reduces the maximum aggregate offering price of American
Depositary Shares (“ADSs”) that may be offered, issued and sold under the Sales Agreement, dated March 17, 2026 (the “Sales
Agreement”), by and between the Company and Leerink Partners LLC (“Leerink Partners”), from $100,000,000 to $80,000,000.
The
Prospectus Supplement supplements the Company’s registration statement on Form F-3 (File No.
333-294392
), which was initially filed
with the Securities and Exchange Commission on March 18, 2026.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited
By:
/s/ John Friend
Name:
John Friend
Title:
Chief Executive Officer
Date:
August 28, 2026
2
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。